Table 2.
Comparison of antimicrobial susceptibilities of blood isolates in patients with non-ventilator and ventilator-associated hospital-acquired pneumonia
| |
Resistance, n (%) |
|
|
|---|---|---|---|
| Antimicrobial agent | Non-ventilator associated (n = 48) | Ventilator-associated (n = 96) | p Value |
| Amikacin |
27 (56.3) |
86 (89.6) |
<0.001 |
| Gentamicin |
32 (68.1) |
88 (93.6) |
<0.001 |
| Ceftazidime |
30 (63.8) |
93 (96.9) |
<0.001 |
| Cefepime |
22 (45.8) |
73 (76.0) |
0.001 |
| Piperacillin/tazobactam |
25 (52.1) |
77 (80.2) |
0.001 |
| Ampicillin/sulbactam |
17 (36.2) |
62 (65.3) |
0.002 |
| Ciprofloxacin |
33 (68.8) |
93 (96.9) |
<0.001 |
| Imipenem |
13 (27.1) |
47 (49.0) |
0.020 |
| Multidrug resistancea | 31 (64.6) | 94 (97.9) | <0.001 |
aDefinition: resistance to three or more of the following classes of antimicrobial agents: anti-pseudomonal cephalosporins, anti-pseudomonal carbapenems, ampicillin/sulbactam, fluoroquinolones, and aminoglycosides.